• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

ERBB3作为胶质母细胞瘤的治疗靶点：过表达可能会产生影响。

ERBB3 as a therapeutic target in glioblastoma: overexpression can make the difference.

作者信息

De Bacco Francesca, Boccaccio Carla

机构信息

Laboratory of Cancer Stem Cell Research, Candiolo Cancer Institute, FPO-IRCCS, Turin, Italy.

Department of Oncology, University of Torino Medical School, Turin, Italy.

出版信息

Mol Cell Oncol. 2021 Oct 27;8(5):1990677. doi: 10.1080/23723556.2021.1990677. eCollection 2021.

DOI:10.1080/23723556.2021.1990677
PMID:34859149
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8632286/
Abstract

By exploiting an integrated experimental platform based on patient-derived cancer stem cells, we identified a glioblastoma subset characterized by inheritable Erb-B2 Receptor Tyrosine Kinase 3 (ERBB3) overexpression, metabolic dependency on ERBB3 signaling, and liability to ERBB3 targeting. We provide insights on why some glioblastomas may rely on ERBB3 and how to recognize them.

摘要

通过利用基于患者来源的癌症干细胞的综合实验平台，我们鉴定出了一个胶质母细胞瘤亚群，其特征为可遗传的表皮生长因子受体-2（ERBB3）过表达、对ERBB3信号传导的代谢依赖性以及对ERBB3靶向治疗的易感性。我们深入探讨了为何某些胶质母细胞瘤可能依赖ERBB3以及如何识别它们。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5e9e/8632286/2726c2ad3dff/KMCO_A_1990677_F0001_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5e9e/8632286/2726c2ad3dff/KMCO_A_1990677_F0001_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5e9e/8632286/2726c2ad3dff/KMCO_A_1990677_F0001_OC.jpg

相似文献

1
ERBB3 as a therapeutic target in glioblastoma: overexpression can make the difference.ERBB3作为胶质母细胞瘤的治疗靶点：过表达可能会产生影响。
Mol Cell Oncol. 2021 Oct 27;8(5):1990677. doi: 10.1080/23723556.2021.1990677. eCollection 2021.
2
New insights into ErbB3 function and therapeutic targeting in cancer.癌症中 ErbB3 功能和治疗靶点的新见解。
Expert Rev Anticancer Ther. 2020 Dec;20(12):1057-1074. doi: 10.1080/14737140.2020.1829485. Epub 2020 Oct 26.
3
Downregulation of ERBB3 decreases the proliferation, migration and invasion of cervical cancer cells though the interaction with MTK-1.ERBB3的下调通过与MTK-1相互作用降低宫颈癌细胞的增殖、迁移和侵袭能力。
Oncol Lett. 2018 Sep;16(3):3453-3458. doi: 10.3892/ol.2018.9088. Epub 2018 Jul 5.
4
MiR-148a inhibits angiogenesis by targeting ERBB3.微小RNA-148a通过靶向表皮生长因子受体3抑制血管生成。
J Biomed Res. 2011 May;25(3):170-7. doi: 10.1016/S1674-8301(11)60022-5.
5
Differential distribution of erbB receptors in human glioblastoma multiforme: expression of erbB3 in CD133-positive putative cancer stem cells.人胶质母细胞瘤中 erbB 受体的差异分布：erbB3 在 CD133 阳性的假定癌症干细胞中的表达。
J Neuropathol Exp Neurol. 2010 Jun;69(6):606-22. doi: 10.1097/NEN.0b013e3181e00579.
6
ERBB3, IGF1R, and TGFBR2 expression correlate with PDGFR expression in glioblastoma and participate in PDGFR inhibitor resistance of glioblastoma cells.ERBB3、IGF1R和TGFBR2的表达与胶质母细胞瘤中的PDGFR表达相关，并参与胶质母细胞瘤细胞对PDGFR抑制剂的耐药性。
Am J Cancer Res. 2018 May 1;8(5):792-809. eCollection 2018.
7
Overexpression of miR-3196 suppresses cell proliferation and induces cell apoptosis through targeting ERBB3 in breast cancer.miR-3196 的过表达通过靶向 ERBB3 抑制乳腺癌细胞增殖并诱导细胞凋亡。
Eur Rev Med Pharmacol Sci. 2018 Dec;22(23):8383-8390. doi: 10.26355/eurrev_201812_16536.
8
Zinc finger transcription factors designed for bispecific coregulation of ErbB2 and ErbB3 receptors: insights into ErbB receptor biology.用于双特异性共调节ErbB2和ErbB3受体的锌指转录因子：对ErbB受体生物学的见解
Mol Cell Biol. 2005 Oct;25(20):9082-91. doi: 10.1128/MCB.25.20.9082-9091.2005.
9
Targeting of erbB3 receptor to overcome resistance in cancer treatment.靶向erbB3受体以克服癌症治疗中的耐药性。
Mol Cancer. 2014 May 8;13:105. doi: 10.1186/1476-4598-13-105.
10
Downregulation of erbB3 abrogates erbB2-mediated tamoxifen resistance in breast cancer cells.erbB3的下调消除了乳腺癌细胞中erbB2介导的他莫昔芬耐药性。
Int J Cancer. 2007 May 1;120(9):1874-82. doi: 10.1002/ijc.22423.

引用本文的文献

1
Mutations in the , , , and Genes and Their Relationship with Resistance to Temozolomide in Patients with High-Grade Gliomas.高级别胶质瘤患者中 、 、 和 基因的突变及其与替莫唑胺耐药性的关系
Biomedicines. 2024 Dec 6;12(12):2777. doi: 10.3390/biomedicines12122777.

本文引用的文献

1
ERBB3 overexpression due to miR-205 inactivation confers sensitivity to FGF, metabolic activation, and liability to ERBB3 targeting in glioblastoma.miR-205 失活导致 ERBB3 过表达使胶质母细胞瘤对 FGF 敏感、代谢激活，并易受 ERBB3 靶向作用影响。
Cell Rep. 2021 Jul 27;36(4):109455. doi: 10.1016/j.celrep.2021.109455.
2
The 2021 WHO Classification of Tumors of the Central Nervous System: a summary.2021 年世卫组织中枢神经系统肿瘤分类：概述。
Neuro Oncol. 2021 Aug 2;23(8):1231-1251. doi: 10.1093/neuonc/noab106.
3
Cell Lineage-Based Stratification for Glioblastoma.
基于细胞谱系的胶质母细胞瘤分层。
Cancer Cell. 2020 Sep 14;38(3):366-379.e8. doi: 10.1016/j.ccell.2020.06.003. Epub 2020 Jul 9.
4
Glioblastoma stem cells: lessons from the tumor hierarchy in a lethal cancer.胶质母细胞瘤干细胞：致命癌症中肿瘤等级的启示。
Genes Dev. 2019 Jun 1;33(11-12):591-609. doi: 10.1101/gad.324301.119.
5
Cancer stem cells revisited.癌症干细胞再探。
Nat Med. 2017 Oct 6;23(10):1124-1134. doi: 10.1038/nm.4409.
6
Systems biology driving drug development: from design to the clinical testing of the anti-ErbB3 antibody seribantumab (MM-121).系统生物学推动药物研发：从抗ErbB3抗体seribantumab（MM - 121）的设计到临床试验
NPJ Syst Biol Appl. 2017 Jan 5;3:16034. doi: 10.1038/npjsba.2016.34. eCollection 2017.
7
Activated ErbB3 Translocates to the Nucleus via Clathrin-independent Endocytosis, Which Is Associated with Proliferating Cells.活化的表皮生长因子受体3（ErbB3）通过网格蛋白非依赖性内吞作用转运至细胞核，这与增殖细胞相关。
J Biol Chem. 2016 Feb 19;291(8):3837-47. doi: 10.1074/jbc.M115.686782. Epub 2015 Dec 30.
8
HER3 comes of age: new insights into its functions and role in signaling, tumor biology, and cancer therapy.HER3 崭露头角：其功能及其在信号转导、肿瘤生物学和癌症治疗中的作用的新见解。
Clin Cancer Res. 2010 Mar 1;16(5):1373-83. doi: 10.1158/1078-0432.CCR-09-1218. Epub 2010 Feb 23.
9
Novel anticancer targets: revisiting ERBB2 and discovering ERBB3.新型抗癌靶点：重新审视ERBB2并发现ERBB3。
Nat Rev Cancer. 2009 Jul;9(7):463-75. doi: 10.1038/nrc2656. Epub 2009 Jun 18.
10
MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling.MET扩增通过激活ERBB3信号通路导致肺癌对吉非替尼耐药。
Science. 2007 May 18;316(5827):1039-43. doi: 10.1126/science.1141478. Epub 2007 Apr 26.